Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nabil Saba

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Oncology|March 19, 2005
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analysesNabil Saba, Fadlo Khuri
Critical Reviews in Oncology/Hematology|May 12, 2005
Retinoids as chemoprevention for head and neck cancer: where do we go from here?Wade Smith, Nabil Saba
Expert Opinion on Investigational Drugs|June 4, 2004
Molecular biological design of novel antineoplastic therapiesMichel Vulfovich, Nabil Saba
Expert Opinion on Therapeutic Targets|August 2, 2007
Targeted therapies in small-cell lung cancerKhaled Fernainy, Nabil Saba
Pharmaceutics|December 7, 2013
Nanotechnology and drug delivery: an update in oncologyTait Jones, Nabil Saba
Journal of Hematotherapy & Stem Cell Research|May 2, 2002
Bone marrow transplantation for nonmalignant diseasesNabil Saba, Thomas Flaig
Expert Opinion on Investigational Drugs|June 4, 2004
Novel targeted agents in the treatment of lung cancerNabil Saba, Fadlo Khuri
Oncology|March 19, 2005
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applicationsNabil Saba, Fadlo Khuri
Current Opinion in Molecular Therapeutics|October 27, 2005
Technology evaluation: mapatumumab, Human Genome Sciences/GlaxoSmithKline/TakedaMichel Vulfovich, Nabil Saba
Journal of Oncology|July 11, 2012
Antiepidermal growth factor receptor therapy in squamous cell carcinoma of the head and neckWalid Shaib, Scott Kono, Nabil Saba
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Oncology|March 19, 2005
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analysesNabil Saba, Fadlo Khuri
Critical Reviews in Oncology/Hematology|May 12, 2005
Retinoids as chemoprevention for head and neck cancer: where do we go from here?Wade Smith, Nabil Saba
Expert Opinion on Investigational Drugs|June 4, 2004
Molecular biological design of novel antineoplastic therapiesMichel Vulfovich, Nabil Saba
Expert Opinion on Therapeutic Targets|August 2, 2007
Targeted therapies in small-cell lung cancerKhaled Fernainy, Nabil Saba
Pharmaceutics|December 7, 2013
Nanotechnology and drug delivery: an update in oncologyTait Jones, Nabil Saba
Journal of Hematotherapy & Stem Cell Research|May 2, 2002
Bone marrow transplantation for nonmalignant diseasesNabil Saba, Thomas Flaig
Expert Opinion on Investigational Drugs|June 4, 2004
Novel targeted agents in the treatment of lung cancerNabil Saba, Fadlo Khuri
Oncology|March 19, 2005
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applicationsNabil Saba, Fadlo Khuri
Current Opinion in Molecular Therapeutics|October 27, 2005
Technology evaluation: mapatumumab, Human Genome Sciences/GlaxoSmithKline/TakedaMichel Vulfovich, Nabil Saba
Journal of Oncology|July 11, 2012
Antiepidermal growth factor receptor therapy in squamous cell carcinoma of the head and neckWalid Shaib, Scott Kono, Nabil Saba
Pageof 4